E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Psychiatry and Psychology [F] - Mental Disorders [F03] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Evaluating the effects of naltrexone on reward function and processing of amphetamine-related cues in amphetamine dependent patients, using functional magnetic resonance imaging. |
|
E.2.2 | Secondary objectives of the trial |
Comparison of reward processing between amphetamine dependent patients and healthy controls.
Evaluation of the effect of naltrexone on pain processing in healthy controls. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Men between the ages 20-55 years
Fulfils DSM-IV diagnosis for amphetamine dependence
Minimum of 2 years history of amphetamine dependence
History of intravenous amphetamine use
Consumed amphetamine for minimum of 12 times in the last 12 weeks
Drug free 1-30 days (minimum 24 hours)
Abstinent from nicotine and caffeine during the testing day
A healthy control group is also selected according to the following inclusion criteria:
Men between 20-55 years, judged to be healthy by the investigator on the basis of medical history, physical examination and vital signs. |
|
E.4 | Principal exclusion criteria |
Fulfils DSM-IV diagnosis of any other substance dependence disorder (except nicotine)
Fulfils DSM-IV diagnosis of any major psychiatric illness (e.g. bipolar affective disorder, schizophrenia)
Left-handedness
No clinical signs of amphetamine intoxication at the day of testing
Traces of cannabis, opiates, cocaine or benzodiazepines in the urine at the day of testing
Traces of alcohol as measured by breathalyser at the day of testing
Implant of pacemaker or any metallic object that might interfere with the magnetic field
Presence of severe somatic disorder (e.g. renal or hepatic failure)
Regular use of medication that may interact with study medication (e.g., opioid pain killers)
Experience with naltrexone during last six months
Known hypersensitivity to naltrexone
The healthy control group will be selected according to the following exclusion criteria:
Fulfils DSM IV diagnosis of any substance dependence disorder in self or in first degree relatives (parents, children or siblings)
Smoker (including snuff or any other nicotine product) and fulfils DSM IV diagnosis of nicotine dependence
Fulfils DSM IV diagnosis of any major psychiatric illness in self or in first degree relatives (parents, children or siblings)
Left-handedness
Traces of cannabis, opiates, cocaine, central amines or benzodiazepines in the urine at test day
Traces of alcohol as measured by breathalyzer at test day
Implant of pacemaker or any metallic object that might interfere with the magnetic field
Use of any concomitant medication
Known hypersensitivity to naltrexone. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
fMRI BOLD signal in the brain reward system during exposure to amphetamine-related cues of different kinds. Functional connectivity as measured by fMRI. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
During cue presentation in the MR camera, at least 60 minutes after intake of study medication. |
|
E.5.2 | Secondary end point(s) |
Behavioral data on subjective craving and experience of pain. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Immediately after cue presentations and painful stimuli, respectively. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | No |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | Yes |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
LVLS. However, if data collection for the last healthy participant is finished before the last patient, the randomization code for the healthy participants may be broken in order to allow analysis of experiments specific for that group. This will not in any way affect the recruitment and study procedures for the patients, which will continue in a double-blind manner. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | 4 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 3 |
E.8.9.2 | In all countries concerned by the trial months | 4 |
E.8.9.2 | In all countries concerned by the trial days | 0 |